For Clinicians
You are here:
PlasmaSEQ Overview
Why PlasmaSEQ
1st Global NGS-based test for Myeloma
Validated for DNA input per sample of as low as 10 ng
1000 Samples validated in 3 countries with 95% accuracy*.
Rapid turnaround time
One stop test for detecting all genomic events including biallelic somatic changes
PlasmaSEQ
*To be released in upcoming Plasmaseq 2.0
FAQ's
What is the minimum amount of Bone Marrow aspirate that is required?
Minimum sample: 2 ml of EDTA-Bone Marrow
Do I still need FISH Testing along with PlasmaSEQ?
PlasmaSEQ is a comprehensive, all-in-one solution for Multiple Myeloma cases. This next-generation sequencing (NGS) method offers an extensive genomic overview, covering IGH translocations, mutations, amplifications, Trisomies & Hyperdiploidies. It eliminates the need for multiple assays such as karyotyping and FISH, while providing in-depth insights.
What is missed by FISH that is covered in PlasmaSEQ?
PlasmaSEQ checks Bi-allelic deletions (CDKN2C), multi-exonic (TP53) deletions that are missed by FISH and helps determine the course of targeted therapy (Immunotherapy).
Can PlasmaSEQ be run in case of low DNA concentration?
PlasmaSEQ can perform testing with as little as 1 nanogram per μL of DNA, ensuring that physicians obtain the maximum amount of information from low sample volume.